Health Economics›Ovarian cancer›Relapsed or recurrent disease platinum-resistant

Relapsed or recurrent disease platinum-resistant

Ovarian cancer · 25 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 17 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Niraparib monotherapy Variant #01	—	R 102 149	28d	~16.1 mo	—	~18	~R 1 838 677 PFS proxy · indirect	7
Pegylated liposomal doxorubicin and Trabectedin Variant #01	—	R 72 252	21d	~7.3 mo	~22.2 mo	~11	~R 794 770 PFS proxy · indirect	2
Olaparib monotherapy Variant #01	HRD	R 59 224	28d	~13.4 mo	~40.9 mo	~15	~R 888 360 PFS proxy · indirect	8
Olaparib monotherapy Variant #01	—	R 59 224	28d	~13.4 mo	~40.9 mo	~15	~R 888 360 PFS proxy · indirect	8
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	~20.4 mo	~51.6 mo	~30	~R 1 717 393 PFS proxy · indirect	3
Topotecan and Bevacizumab Variant #01	—	R 56 665	28d	~6.7 mo	—	~8	~R 453 323 PFS proxy · indirect	1
Pegylated liposomal doxorubicin and Bevacizumab Variant #01	—	R 51 764	28d	~6.7 mo	~13.0 mo	~8	~R 414 114 PFS proxy · indirect	3
Paclitaxel and Bevacizumab Variant #01	—	R 40 037	28d	~6.7 mo	~13.0 mo	~8	~R 320 296 PFS proxy · indirect	3
Paclitaxel and Pazopanib Variant #01	—	R 24 418	28d	~6.4 mo	—	~7	~R 170 927 PFS proxy · indirect	1
Pazopanib monotherapy Variant #01	—	R 22 754	28d	~17.9 mo	—	~20	~R 455 071 PFS proxy · indirect	1
Pegylated liposomal doxorubicin monotherapy Variant #01	—	R 15 300	28d	~3.9 mo	~13.5 mo	~5	~R 76 500 PFS proxy · indirect	18
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	~3.3 mo	~15.0 mo	~2	~R 28 426 PFS proxy · indirect	4
Gemcitabine and Pegylated liposomal doxorubicin Variant #01	—	R 13 043	21d	—	—	—	—	—
Topotecan monotherapy Variant #01	—	R 11 563	21d	~4.0 mo	~13.4 mo	~6	~R 69 379 PFS proxy · indirect	9
Etoposide monotherapy Variant #01	—	R 2 872	28d	—	—	—	—	—
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	~4.4 mo	~14.0 mo	~5	~R 11 098 PFS proxy · indirect	18
Carboplatin monotherapy Variant #01	—	R 1 231	21d	5.8 mo	21.0 mo	9	R 11 076 PFS proxy	2
Vinorelbine monotherapy Variant #01	—	R 583	21d	—	~9.0 mo	—	—	2
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	~3.2 mo	~9.5 mo	~4	~R 973 PFS proxy · indirect	83
Trabectedin monotherapy N/A - secondary systemic drug	—	R 109	28d	~4.4 mo	~13.7 mo	~5	~R 543 PFS proxy · indirect	4
Pemetrexed monotherapy N/A - secondary systemic drug	—	R 69	21d	—	~9.0 mo	—	—	2
Mirvetuximab soravtansine monotherapy Variant #01 Partial	—	—	21d	~5.1 mo	~16.5 mo	~8	—	2
Rucaparib monotherapy Variant #01 Partial	—	—	28d	~20.2 mo	~27.7 mo	~22	—	7
Treosulfan monotherapy Variant #01 Partial	—	—	28d	—	~9.4 mo	—	—	1
Altretamine monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—

25 of 25 regimens shown